Bliss GVS Pharma Ltd

Resolution 1

• Ordinary resolution to appoint Hetul Mehta as Non-Executive Non-Independent Director, effective Sept 28, 2026, liable to rotation.

Resolution 2

• Ordinary resolution to appoint Amar Shah as Non-Executive Non-Independent Director, effective Sept 28, 2026, liable to rotation.

Resolution 3

• Ordinary resolution to appoint Pramod Kasat as Non-Executive Non-Independent Director, effective Sept 28, 2026, liable to rotation.

Timeline

• Results to be announced by Nov 17, 2026; e-voting Oct 16–Nov 14, 2026.

Capital / Securities

• ESOP Allotment Committee approved allotment of 53,500 equity shares under Bliss GVS ESOP-2019 on Oct 15, 2026.
• Total issued equity shares increased to 10,63,83,972; par value Re 1 per share.
• Exercise price per share is Rs 43; premium Rs 42.
• ISIN INE416D01022; shares rank pari passu with existing equity.
• Lock-in for six months from allotment, expiring April 14, 2027.

Promoter reclassification post-acquisition

• Promoter reclassification completed after change in control via SPA and open offer.
• SPA dated May 23, 2026; completion of open offer on September 28, 2026.
• Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited acquired control.
• Board noted reclassification and updated promoter/promoter group list.
• Updated promoter list includes 15 entities; 1-2 are Promoters, 3-15 Promoter Group.
• Regulatory disclosures under SEBI LODR Regulation 31A(10) completed; record with exchanges.

Bliss GVS Pharma Limited trading window closed from October 01, 2026 till completion of 48 hours after the announcement of the Unaudited Financial Results for the quarter and half year ended September 30, 2026 generally made available to the public.

Meeting Details

• Board meeting scheduled for October 01, 2026 at the registered office via video conferencing.
• Time of meeting not disclosed.

Key Agenda Items

• Establishment of Senior Executive Employee Stock Option Plan 2026.
• Establishment of Employee Stock Option Plan 2026.

Other Notes

• No additional material notes disclosed.

Promoter reclassification and compliance

• Outgoing Promoters ceased to be in control; pre-completion 34.82% held by 25 entities, post 0.01%.
• Promoter reclassification to public under Regulation 31A(10) of the SEBI Listing Regulations.
• Open offer completed; Purchaser/PAC acquired control of the company.
• SPA dated May 23, 2026; DOA dated July 17, 2026; PAC assigned rights.
• LOF disclosures to Incoming Promoter; company complies with Reg 31A(3)(b) and 31A(4).

Promoter change and shareholding

• PAC and Purchaser hold 47.95% post Open Offer.
• Promoter status conferred to Anupam Rasayan India Ltd and PAC.

Director appointments

• Hetul Krishnakant Mehta appointed Additional Director (Non-Executive Non-Independent) effective Sep 28, 2026.
• Amar Dilip Shah appointed Additional Director (Non-Executive Non-Independent) effective Sep 28, 2026.
• Pramod Badrinarayan Kasat appointed Additional Director (Non-Executive Non-Independent) effective Sep 28, 2026.

MD resignation

• Mr. Narsimha Shibroor Kamath resigns as Managing Director effective Sep 28, 2026.

Shareholder voting and approvals

• Draft Postal Ballot Notice approved for appointment of three Non-Executive Non-Independent Directors.

Resolution and outcome

• Appointment of Santosh Parab (DIN: 01622988) as Non-Executive, Non-Independent Director (Ordinary Resolution).
• Term not disclosed; no director experience details provided in extract.
• Voting: 97.04% in favour, 2.96% against; total votes polled 10,62,43,972.
• Voting period Aug 21–Sep 19, 2026; Cut-off date Aug 14, 2026.
• No change in share capital or other material corporate actions.